• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Astellas, Iota ink wireless implant pact

Astellas, Iota ink wireless implant pact

September 18, 2019 By Sean Whooley

Iota Biosciences said last week that it has entered a research and development agreement with Astellas Pharma to explore new biosensing and treatment measures with wireless implantable medical devices.

The deal will pair the companies up to design detailed specifications of the implantable devices and conduct preclinical studies for several diseases, according to a news release.

Berkeley, Calif.-based Iota specializes in bioelectronics, developing battery-free and wireless millimeter-sized implantable devices to pair with Astellas’ Rx prescription drug business. Tokyo-based Astellas invested in Iota through its U.S. subsidiary, Astellas Venture Management LLC, in May 2018.

Iota said it expects the battery-free and wireless devices it is developing will enable new classes of biosensors to monitor the condition of tissues and organs, while new treatment devices could be designed to provide stimulation to nerves and muscles.

“We envision a future in which our ultra-small implantable devices will be used in combination with, or as an alternative to, conventional diagnostics and therapies,” Iota co-founders & co-CEOs Jose Carmena and Michel Maharbiz said in the release. “Through our collaboration with Astellas, we expect to make our innovative technologies available to patients around the world.”

“We are very pleased to be able to collaborate with Iota, led by pioneers in the field of bioelectronics,” added Astellas chief strategy officer Naoki Okamura. “With our Rx+ strategy, we aim to create innovative healthcare solutions that combine our strengths in the prescription drug (Rx) business developed over many years with technologies and knowledge from fields outside of the traditional Rx space. This agreement is part of our efforts, and we will continue to actively invest in this field.”

Astellas agreed to a $625 million overseas distribution deal with Frequency Therapeutics in July. Astellas said the agreement with Iota will have limited impact on the company’s financial results in the fiscal year ending March 31, 2020.

Filed Under: Bioelectronic Medicine, Business/Financial News, Featured, Implants, News Well, Research & Development Tagged With: Astellas Pharma, iota Biosciences

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy